

Biomedical Interventions for HIV Prevention Working Group Meeting

18-Sep	What	Who
11:30-12:30	Lunch; Registration	All
12:30-12:45	Welcome & Overview; party rules	V Miller
12:45-1:00	Working Group Chairs & Sponsor Perspective	W Cates, M Cohen, N Hellmann
Session I: Checking the time on the intervention clock: <i>Where are we today and why are we still here?</i>		
1:00-3:00		Moderators: W Cates, T Quinn
Rapporteur: C Lubinski; L Barnes		
<p><u>Session I objectives:</u> 1. Review the current status of research within each program: what do we know; when will we know more? 2. What are the key research questions not being addressed currently? 3. Identify barriers, constraints (choke points) that prevent us from moving forward more rapidly</p>		
1:00-1:10	Female-Controlled Barrier Methods	A Van der Straten
1:10-1:20	Male Circumcision	R Bailey
1:20-1:30	HSV-2 Treatment	C Celum (for P Mayaud)
1:30-1:40	Microbicides 1 (basic science)	J Moore
1:40-1:50	Microbicides 2 (clinical science)	R Shattock
1:50-2:00	PREP	R Grant
2:00-2:10	Index Partner Treatment	M Cohen
2:10-3:15	Discussion	All
3:15-3:40	<i>Coffee Break</i>	
3:40-6:30	Session II: Feasibility & Realism	Moderators: M Cohen, T Coates

Rapporteur: M Ruiz; D Glidden

Session II objectives: Review why an intervention would or wouldn't work in specific populations based on assumptions made when modeling or projecting effectiveness, from the biologic, behavioral, individual and population coverage perspective (going beyond the good science)

3:40 - 4:00	Female Barrier Methods -- why they will be effective	M Warren
	Female Barrier Methods -- why they may not be effective	C Hankins
4:00 - 4:20	Male Circumcision -- why it will be effective	R Gray
	Male Circumcision -- why it may not be effective	M Waver
4:40 - 4:40	HSV-2 Treatment -- why it will be effective	C Celum
	HSV-2 Treatment -- why it may not be effective	S Hillier
4:40 - 5:00	Microbicides -- why they will be effective	Z Rosenberg
	Microbicides -- why they may not be effective	C Hendrix
5:00 - 5:20	PREP -- why it will be effective	M Wainberg
	PREP -- why it may not be effective	W Cates
5:20 - 5:40	Index Partner Treatment -- why it will be effective	W El-Sadr
	Index Partner Treatment -- why it may not be effective	A Ghani
5:40 - 6:30	Discussion	

7:00-9:00 Reception

19-Sep

What

Who

7:00-8:00 Breakfast

8:00 - 9:00 Session IIIA: Prevention Trial Sites

Moderators: A Greenberg, L Paxton

Rapporteur: N Fuchs-Montgomery, K Douville

Session IIIA objectives: 1. Develop recommendations to address issues regarding prevention trial sites, including a) number of available sites; b) identifying appropriate sites; c) building site capacity; d) more efficient use of sites. 2. How do sponsors/programs contribute to site development? 3. Is an ongoing discussion/exchange necessary?

Discussants: C Ryan, J Sanchez, L Claypool, L V Damme, C Williams, B Auvert, P Johnson

8:00-9:00 Session IIIB: ARV Issues

Moderators: T Folks, K Mayer

Rapporteur: B Cheng; M-P de Bethune

Session IIIB objectives: 1. Discuss criteria for recommending ARVs or combinations of ARVs for prevention interventions. 2. What are the minimal efficacy/maximum toxicity limits? 3. Do prevention ARVs need to be distinct from therapeutic ARVs? 4. Is an ongoing discussion/exchange necessary?

Discussants: C Boucher, H Mayer, K Struble, Y Halima, J Rooney

9:00 - 9:15 **Joint Session III: Summary feedback to all participants** **L Paxton, K Mayer**

9:15-11:45 **Session IV: Priorities for Research: Can we rewind the intervention clock?** **Moderators: S Bertozzi, J Lange**

Rapporteur: R Johnston; D Stanton

Session V objectives: 1. To recap biomedical prevention working group discussions on criteria for research priorities and constraints keeping research from happening; 2. How do we fill these gaps?

- Recap of biomedical prevention working group discussion thus far S Bertozzi; J Lange
D Bolognesi; S Hodder
1. Gaps in information: what information do we need to know to answer the question
 2. Gaps in activity: Mismatch between priorities and what is currently happening P Harrison; B Bazin
 3. Gaps in facilitation: finding the mechanism to make it happen M Lederman; M Berrey
 4. Reality check: on-the-ground perspective E Clarke; E Bukusi
 5. Way forward? K Holmes

11:45-12:00 **Wrap up & Next Steps** **W Cates, M Cohen, V Miller**

12:00-1:00 Box lunch available

Notes

